ID   PKN1_HUMAN              Reviewed;         942 AA.
AC   Q16512; A8K7W5; B2R9R4; B3KVN3; Q15143; Q504U4; Q8IUV5; Q9UD44;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   22-SEP-2009, sequence version 2.
DT   05-OCT-2010, entry version 131.
DE   RecName: Full=Serine/threonine-protein kinase N1;
DE            EC=2.7.11.13;
DE   AltName: Full=Protease-activated kinase 1;
DE            Short=PAK-1;
DE   AltName: Full=Protein kinase C-like 1;
DE   AltName: Full=Protein kinase C-like PKN;
DE   AltName: Full=Protein kinase PKN-alpha;
DE   AltName: Full=Protein-kinase C-related kinase 1;
DE   AltName: Full=Serine-threonine protein kinase N;
GN   Name=PKN1; Synonyms=PAK1, PKN, PRK1, PRKCL1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND MUTAGENESIS OF LYS-644.
RC   TISSUE=Hippocampus;
RX   MEDLINE=94183274; PubMed=8135837; DOI=10.1006/bbrc.1994.1313;
RA   Mukai H., Ono Y.;
RT   "A novel protein kinase with leucine zipper-like sequences: its
RT   catalytic domain is highly homologous to that of protein kinase C.";
RL   Biochem. Biophys. Res. Commun. 199:897-904(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Fetal brain;
RX   MEDLINE=95154310; PubMed=7851406;
RX   DOI=10.1111/j.1432-1033.1995.tb20395.x;
RA   Palmer R.H., Ridden J., Parker P.J.;
RT   "Cloning and expression patterns of two members of a novel protein-
RT   kinase-C-related kinase family.";
RL   Eur. J. Biochem. 227:344-351(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND
RP   VARIANTS ILE-555 AND ILE-901.
RC   TISSUE=Kidney, Synovium, and Thymus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3), AND VARIANT
RP   ILE-901.
RC   TISSUE=Brain, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 700-800 (ISOFORMS 1/2), AND VARIANT
RP   VAL-718.
RX   MEDLINE=95080426; PubMed=7988719; DOI=10.1016/0014-5793(94)01202-4;
RA   Palmer R.H., Ridden J., Parker P.J.;
RT   "Identification of multiple, novel, protein kinase C-related gene
RT   products.";
RL   FEBS Lett. 356:5-8(1994).
RN   [7]
RP   FUNCTION, AND INTERACTION WITH MARCKS.
RX   PubMed=8557118; DOI=10.1016/0014-5793(95)01454-3;
RA   Palmer R.H., Schonwasser D.C., Rahman D., Pappin D.J., Herget T.,
RA   Parker P.J.;
RT   "PRK1 phosphorylates MARCKS at the PKC sites: serine 152, serine 156
RT   and serine 163.";
RL   FEBS Lett. 378:281-285(1996).
RN   [8]
RP   FUNCTION, AND INTERACTION WITH NEFH; NEFL AND NEFM.
RX   PubMed=8621664; DOI=10.1074/jbc.271.16.9816;
RA   Mukai H., Toshimori M., Shibata H., Kitagawa M., Shimakawa M.,
RA   Miyahara M., Sunakawa H., Ono Y.;
RT   "PKN associates and phosphorylates the head-rod domain of
RT   neurofilament protein.";
RL   J. Biol. Chem. 271:9816-9822(1996).
RN   [9]
RP   ENZYME REGULATION, AND INTERACTION WITH RHOA.
RX   MEDLINE=96165390; PubMed=8571126; DOI=10.1126/science.271.5249.645;
RA   Watanabe G., Saito Y., Madaule P., Ishizaki T., Fujisawa K., Morii N.,
RA   Mukai H., Ono Y., Kakizuka A., Narumiya S.;
RT   "Protein kinase N (PKN) and PKN-related protein rhophilin as targets
RT   of small GTPase Rho.";
RL   Science 271:645-648(1996).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH GFAP AND VIM.
RX   PubMed=9175763; DOI=10.1006/bbrc.1997.6669;
RA   Matsuzawa K., Kosako H., Inagaki N., Shibata H., Mukai H., Ono Y.,
RA   Amano M., Kaibuchi K., Matsuura Y., Azuma I., Inagaki M.;
RT   "Domain-specific phosphorylation of vimentin and glial fibrillary
RT   acidic protein by PKN.";
RL   Biochem. Biophys. Res. Commun. 234:621-625(1997).
RN   [11]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH RHOB.
RX   PubMed=9478917; DOI=10.1074/jbc.273.9.4811;
RA   Mellor H., Flynn P., Nobes C.D., Hall A., Parker P.J.;
RT   "PRK1 is targeted to endosomes by the small GTPase, RhoB.";
RL   J. Biol. Chem. 273:4811-4814(1998).
RN   [12]
RP   ENZYME REGULATION, PROTEOLYTIC PROCESSING, AND MUTAGENESIS OF ASP-108;
RP   ASP-451; ASP-454; ASP-558 AND ASP-560.
RX   PubMed=9751706; DOI=10.1073/pnas.95.20.11566;
RA   Takahashi M., Mukai H., Toshimori M., Miyamoto M., Ono Y.;
RT   "Proteolytic activation of PKN by caspase-3 or related protease during
RT   apoptosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:11566-11571(1998).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH MAPT.
RX   PubMed=11104762; DOI=10.1074/jbc.M007427200;
RA   Taniguchi T., Kawamata T., Mukai H., Hasegawa H., Isagawa T.,
RA   Yasuda M., Hashimoto T., Terashima A., Nakai M., Mori H., Ono Y.,
RA   Tanaka C.;
RT   "Phosphorylation of tau is regulated by PKN.";
RL   J. Biol. Chem. 276:10025-10031(2001).
RN   [14]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH ANDR.
RX   PubMed=12514133; DOI=10.1093/emboj/cdg023;
RA   Metzger E., Muller J.M., Ferrari S., Buettner R., Schule R.;
RT   "A novel inducible transactivation domain in the androgen receptor:
RT   implications for PRK in prostate cancer.";
RL   EMBO J. 22:270-280(2003).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-916, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=15302935; DOI=10.1073/pnas.0404720101;
RA   Beausoleil S.A., Jedrychowski M., Schwartz D., Elias J.E., Villen J.,
RA   Li J., Cohn M.A., Cantley L.C., Gygi S.P.;
RT   "Large-scale characterization of HeLa cell nuclear phosphoproteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:12130-12135(2004).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-376, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [17]
RP   INTERACTION WITH S.TYPHIMURIUM SSPH1.
RX   PubMed=16611232; DOI=10.1111/j.1462-5822.2005.00670.x;
RA   Haraga A., Miller S.I.;
RT   "A Salmonella type III secretion effector interacts with the mammalian
RT   serine/threonine protein kinase PKN1.";
RL   Cell. Microbiol. 8:837-846(2006).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-562, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-562 AND SER-916, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=17192257; DOI=10.1074/mcp.T600062-MCP200;
RA   Wissing J., Jaensch L., Nimtz M., Dieterich G., Hornberger R.,
RA   Keri G., Wehland J., Daub H.;
RT   "Proteomics analysis of protein kinases by target class-selective
RT   prefractionation and tandem mass spectrometry.";
RL   Mol. Cell. Proteomics 6:537-547(2007).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-778, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-205; THR-353; SER-533;
RP   SER-537; SER-559 AND SER-916, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-533; SER-537; SER-559;
RP   SER-562 AND SER-916, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
RN   [24]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT SER-533; SER-537; SER-559; SER-561; SER-562 AND
RP   SER-916, AND MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [25]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-644.
RX   PubMed=18066052; DOI=10.1038/ncb1668;
RA   Metzger E., Yin N., Wissmann M., Kunowska N., Fischer K.,
RA   Friedrichs N., Patnaik D., Higgins J.M., Potier N., Scheidtmann K.H.,
RA   Buettner R., Schule R.;
RT   "Phosphorylation of histone H3 at threonine 11 establishes a novel
RT   chromatin mark for transcriptional regulation.";
RL   Nat. Cell Biol. 10:53-60(2008).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-205; SER-533; SER-537;
RP   SER-559; SER-562; THR-914 AND SER-916, AND MASS SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [27]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-448, AND MASS SPECTROMETRY.
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [28]
RP   FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, AND INTERACTION WITH HDAC5;
RP   HDAC7 AND HDAC9.
RX   PubMed=20188095; DOI=10.1016/j.febslet.2010.02.057;
RA   Harrison B.C., Huynh K., Lundgaard G.L., Helmke S.M., Perryman M.B.,
RA   McKinsey T.A.;
RT   "Protein kinase C-related kinase targets nuclear localization signals
RT   in a subset of class IIa histone deacetylases.";
RL   FEBS Lett. 584:1103-1110(2010).
RN   [29]
RP   INTERACTION WITH PRKCB.
RX   PubMed=20228790; DOI=10.1038/nature08839;
RA   Metzger E., Imhof A., Patel D., Kahl P., Hoffmeyer K., Friedrichs N.,
RA   Muller J.M., Greschik H., Kirfel J., Ji S., Kunowska N.,
RA   Beisenherz-Huss C., Gunther T., Buettner R., Schule R.;
RT   "Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation
RT   at histone H3K4.";
RL   Nature 464:792-796(2010).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 13-98 IN COMPLEX WITH RHOA.
RX   PubMed=10619026; DOI=10.1016/S1097-2765(00)80389-5;
RA   Maesaki R., Ihara K., Shimizu T., Kuroda S., Kaibuchi K.,
RA   Hakoshima T.;
RT   "The structural basis of Rho effector recognition revealed by the
RT   crystal structure of human RhoA complexed with the effector domain of
RT   PKN/PRK1.";
RL   Mol. Cell 4:793-803(1999).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 13-98.
RX   PubMed=10388627; DOI=10.1006/jsbi.1999.4114;
RA   Maesaki R., Shimizu T., Ihara K., Kuroda S., Kaibuchi K.,
RA   Hakoshima T.;
RT   "Biochemical and crystallographic characterization of a Rho effector
RT   domain of the protein serine/threonine kinase N in a complex with
RT   RhoA.";
RL   J. Struct. Biol. 126:166-170(1999).
RN   [32]
RP   STRUCTURE BY NMR OF 116-199 IN COMPLEX WITH RAC1.
RX   PubMed=14514689; DOI=10.1074/jbc.M304313200;
RA   Owen D., Lowe P.N., Nietlispach D., Brosnan C.E., Chirgadze D.Y.,
RA   Parker P.J., Blundell T.L., Mott H.R.;
RT   "Molecular dissection of the interaction between the small G proteins
RT   Rac1 and RhoA and protein kinase C-related kinase 1 (PRK1).";
RL   J. Biol. Chem. 278:50578-50587(2003).
RN   [33]
RP   STRUCTURE BY NMR OF 122-199 IN COMPLEX WITH RAC1.
RX   PubMed=18006505; DOI=10.1074/jbc.M706760200;
RA   Modha R., Campbell L.J., Nietlispach D., Buhecha H.R., Owen D.,
RA   Mott H.R.;
RT   "The Rac1 polybasic region is required for interaction with its
RT   effector PRK1.";
RL   J. Biol. Chem. 283:1492-1500(2008).
RN   [34]
RP   VARIANTS [LARGE SCALE ANALYSIS] CYS-185; GLU-197; TRP-436; GLN-520;
RP   ILE-555; GLN-635; VAL-718; LEU-873; ILE-901 AND VAL-921.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: PKC-related serine/threonine-protein kinase involved in
CC       various processes such as regulation of the intermediate filaments
CC       of the actin cytoskeleton and transcription regulation. Regulates
CC       the cytoskeletal network by phosphorylating proteins such as VIM
CC       and neurofilament proteins NEFH, NEFL and NEFM, leading to inhibit
CC       their polymerization. Phosphorylates 'Ser-575', 'Ser-637' and
CC       'Ser-669' of MAPT/Tau, lowering its ability to bind to
CC       microtubules, resulting in disruption of tubulin assembly. Acts as
CC       a key coactivator of androgen receptor (ANDR)-dependent
CC       transcription, by being recruited to ANDR target genes and
CC       specifically mediating phosphorylation of 'Thr-11' of histone H3
CC       (H3T11ph), a specific tag for epigenetic transcriptional
CC       activation that promotes demethylation of histone H3 'Lys-9'
CC       (H3K9me) by KDM4C/JMJD2C. Phosphorylates HDAC5, HDAC7 and HDAC9,
CC       leading to impair their import in the nucleus. Phosphorylates
CC       'Thr-38' of PPP1R14A, 'Ser-159', 'Ser-163' and 'Ser-170' of
CC       MARCKS, and GFAP. Able to phosphorylate RPS6 in vitro.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Kinase activity is activated upon binding to
CC       Rho proteins (RHOA, RHOB and RAC1). Activated by lipids,
CC       particularly cardiolipin and to a lesser extent by other acidic
CC       phospholipids. Activated by caspase-3 (CASP3) cleavage during
CC       apoptosis. Two specific sites, Thr-774 (activation loop of the
CC       kinase domain) and Ser-916 (turn motif), need to be phosphorylated
CC       for its full activation.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=20.6 uM for HDAC5;
CC   -!- SUBUNIT: Interacts with ZA20D3 (By similarity). Interacts with
CC       ANDR. Interacts with PRKCB. Interacts (via REM 1 and REM 2
CC       repeats) with RAC1. Interacts (via REM 1 repeat) with RHOA.
CC       Interacts with RHOB. In case of infection, interacts with
CC       S.typhimurium protein sspH1.
CC   -!- INTERACTION:
CC       P46734:MAP2K3; NbExp=1; IntAct=EBI-602382, EBI-602462;
CC       P52564:MAP2K6; NbExp=1; IntAct=EBI-602382, EBI-448135;
CC       P53778:MAPK12; NbExp=1; IntAct=EBI-602382, EBI-602406;
CC       Q16539:MAPK14; NbExp=1; IntAct=EBI-602382, EBI-73946;
CC       Q9NYL2:MLTK; NbExp=1; IntAct=EBI-602382, EBI-602273;
CC       P61586:RHOA; NbExp=1; IntAct=EBI-602382, EBI-446668;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Endosome. Cell membrane;
CC       Peripheral membrane protein. Note=Associates with chromatin in a
CC       ligand-dependent manner. Localization to endosomes is mediated via
CC       its interaction with RHOB. Association to the cell membrane is
CC       dependent on Ser-374 phosphorylation.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q16512-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q16512-2; Sequence=VSP_038143;
CC         Note=No experimental confirmation available;
CC       Name=3;
CC         IsoId=Q16512-3; Sequence=VSP_039213, VSP_039214;
CC         Note=No experimental confirmation available;
CC   -!- TISSUE SPECIFICITY: Found ubiquitously. Expressed in heart, brain,
CC       placenta, lung, skeletal muscle, kidney and pancreas.
CC   -!- DOMAIN: The C1 domain does not bind the diacylglycerol (DAG).
CC   -!- PTM: Autophosphorylated; preferably on serine.
CC   -!- PTM: Activated by limited proteolysis with trypsin (By
CC       similarity).
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. PKC subfamily.
CC   -!- SIMILARITY: Contains 1 AGC-kinase C-terminal domain.
CC   -!- SIMILARITY: Contains 1 C2 domain.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SIMILARITY: Contains 3 REM (Hr1) repeats.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D26181; BAA05169.1; -; mRNA.
DR   EMBL; S75546; AAB33345.1; -; mRNA.
DR   EMBL; U33053; AAC50209.1; -; mRNA.
DR   EMBL; AK123007; BAG53845.1; -; mRNA.
DR   EMBL; AK292130; BAF84819.1; -; mRNA.
DR   EMBL; AK313886; BAG36611.1; -; mRNA.
DR   EMBL; AC008569; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC040061; AAH40061.1; -; mRNA.
DR   EMBL; BC094766; AAH94766.1; -; mRNA.
DR   IPI; IPI00002803; -.
DR   IPI; IPI00412672; -.
DR   IPI; IPI00965991; -.
DR   PIR; JC2129; JC2129.
DR   PIR; S51162; S51162.
DR   RefSeq; NP_002732.3; -.
DR   RefSeq; NP_998725.1; -.
DR   UniGene; Hs.466044; -.
DR   PDB; 1CXZ; X-ray; 2.20 A; B=13-98.
DR   PDB; 1URF; NMR; -; A=122-199.
DR   PDB; 2RMK; NMR; -; B=122-199.
DR   PDBsum; 1CXZ; -.
DR   PDBsum; 1URF; -.
DR   PDBsum; 2RMK; -.
DR   ProteinModelPortal; Q16512; -.
DR   IntAct; Q16512; 13.
DR   MINT; MINT-118694; -.
DR   STRING; Q16512; -.
DR   PhosphoSite; Q16512; -.
DR   PRIDE; Q16512; -.
DR   Ensembl; ENST00000242783; ENSP00000242783; ENSG00000123143.
DR   Ensembl; ENST00000342216; ENSP00000343325; ENSG00000123143.
DR   GeneID; 5585; -.
DR   KEGG; hsa:5585; -.
DR   CTD; 5585; -.
DR   GeneCards; GC19P014544; -.
DR   H-InvDB; HIX0027472; -.
DR   HGNC; HGNC:9405; PKN1.
DR   HPA; CAB010278; -.
DR   HPA; HPA003982; -.
DR   MIM; 601032; gene.
DR   PharmGKB; PA33769; -.
DR   eggNOG; prNOG11664; -.
DR   HOVERGEN; HBG108317; -.
DR   OMA; TRAGHPF; -.
DR   BRENDA; 2.7.11.13; 247.
DR   Pathway_Interaction_DB; ar_tf_pathway; Regulation of Androgen receptor activity.
DR   Pathway_Interaction_DB; p38gammadeltapathway; Signaling mediated by p38-gamma and p38-delta.
DR   NextBio; 21660; -.
DR   PMAP-CutDB; Q16512; -.
DR   ArrayExpress; Q16512; -.
DR   Bgee; Q16512; -.
DR   CleanEx; HS_PKN1; -.
DR   Genevestigator; Q16512; -.
DR   GermOnline; ENSG00000123143; Homo sapiens.
DR   GO; GO:0005768; C:endosome; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0050681; F:androgen receptor binding; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0017049; F:GTP-Rho binding; IDA:UniProtKB.
DR   GO; GO:0042393; F:histone binding; IDA:UniProtKB.
DR   GO; GO:0042826; F:histone deacetylase binding; IDA:UniProtKB.
DR   GO; GO:0035402; F:histone kinase activity (H3-T11 specific); IDA:UniProtKB.
DR   GO; GO:0030374; F:ligand-dependent nuclear receptor transcrip...; IDA:UniProtKB.
DR   GO; GO:0004697; F:protein kinase C activity; IEA:EC.
DR   GO; GO:0005080; F:protein kinase C binding; IPI:UniProtKB.
DR   GO; GO:0048365; F:Rac GTPase binding; IDA:UniProtKB.
DR   GO; GO:0007257; P:activation of JUN kinase activity; TAS:ProtInc.
DR   GO; GO:0034339; P:regulation of transcription from RNA polyme...; IDA:UniProtKB.
DR   GO; GO:0006350; P:transcription; IEA:UniProtKB-KW.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR000008; C2_Ca-dep.
DR   InterPro; IPR008973; C2_Ca/lipid-bd_dom_CaLB.
DR   InterPro; IPR011072; HR1_rho-bd.
DR   InterPro; IPR000861; HR1_rpt_rho-bd.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   InterPro; IPR002290; Ser/Thr_prot_kinase_dom.
DR   Gene3D; G3DSA:1.10.287.160; HR1_rho-bd; 3.
DR   Pfam; PF02185; HR1; 3.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00742; Hr1; 3.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF49562; C2_CaLB; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   SUPFAM; SSF46585; PKN_effector; 3.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50004; C2; FALSE_NEG.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Cell membrane; Chromatin regulator; Complete proteome; Cytoplasm;
KW   Endosome; Kinase; Membrane; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Repeat; Serine/threonine-protein kinase;
KW   Transcription; Transcription regulation; Transferase.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2    942       Serine/threonine-protein kinase N1.
FT                                /FTId=PRO_0000055719.
FT   REPEAT       34    110       REM 1.
FT   REPEAT      123    209       REM 2.
FT   REPEAT      210    291       REM 3.
FT   DOMAIN      325    461       C2.
FT   DOMAIN      615    874       Protein kinase.
FT   DOMAIN      875    942       AGC-kinase C-terminal.
FT   NP_BIND     621    629       ATP (By similarity).
FT   ACT_SITE    740    740       Proton acceptor (By similarity).
FT   BINDING     644    644       ATP (By similarity).
FT   SITE        108    109       Cleavage; by caspase-3.
FT   SITE        454    455       Cleavage; by caspase-3.
FT   SITE        558    559       Cleavage; by caspase-3.
FT   MOD_RES       2      2       N-acetylalanine.
FT   MOD_RES     205    205       Phosphoserine.
FT   MOD_RES     353    353       Phosphothreonine.
FT   MOD_RES     374    374       Phosphoserine (By similarity).
FT   MOD_RES     376    376       Phosphoserine.
FT   MOD_RES     448    448       N6-acetyllysine.
FT   MOD_RES     533    533       Phosphoserine.
FT   MOD_RES     537    537       Phosphoserine.
FT   MOD_RES     559    559       Phosphoserine.
FT   MOD_RES     561    561       Phosphoserine.
FT   MOD_RES     562    562       Phosphoserine.
FT   MOD_RES     774    774       Phosphothreonine (Probable).
FT   MOD_RES     778    778       Phosphothreonine.
FT   MOD_RES     914    914       Phosphothreonine.
FT   MOD_RES     916    916       Phosphoserine.
FT   VAR_SEQ       1      7       MASDAVQ -> MAEANNPSEQELE (in isoform 2).
FT                                /FTId=VSP_038143.
FT   VAR_SEQ     603    603       S -> R (in isoform 3).
FT                                /FTId=VSP_039213.
FT   VAR_SEQ     604    942       Missing (in isoform 3).
FT                                /FTId=VSP_039214.
FT   VARIANT     185    185       R -> C (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_042337.
FT   VARIANT     197    197       A -> E.
FT                                /FTId=VAR_042338.
FT   VARIANT     436    436       R -> W (in dbSNP:rs35132656).
FT                                /FTId=VAR_042339.
FT   VARIANT     520    520       R -> Q (in dbSNP:rs56273055).
FT                                /FTId=VAR_042340.
FT   VARIANT     555    555       L -> I (in dbSNP:rs34309238).
FT                                /FTId=VAR_042341.
FT   VARIANT     635    635       R -> Q (in dbSNP:rs35416389).
FT                                /FTId=VAR_042342.
FT   VARIANT     718    718       I -> V (in dbSNP:rs2230539).
FT                                /FTId=VAR_042343.
FT   VARIANT     873    873       F -> L (in a breast infiltrating ductal
FT                                carcinoma sample; somatic mutation).
FT                                /FTId=VAR_042344.
FT   VARIANT     901    901       V -> I (in dbSNP:rs10846).
FT                                /FTId=VAR_014937.
FT   VARIANT     921    921       A -> V (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_042345.
FT   MUTAGEN     108    108       D->A: Abolishes cleavage by caspase-3 and
FT                                formation of AF1 fragment.
FT   MUTAGEN     451    451       D->A: Abolishes cleavage by caspase-3 and
FT                                formation of 70 kDa fragment.
FT   MUTAGEN     454    454       D->A: Abolishes cleavage by caspase-3 and
FT                                formation of 70 kDa fragment.
FT   MUTAGEN     558    558       D->A: Abolishes cleavage by caspase-3 and
FT                                formation of AF3 fragment.
FT   MUTAGEN     560    560       D->A: Abolishes cleavage by caspase-3 and
FT                                formation of AF3 fragment.
FT   MUTAGEN     644    644       K->E: Abolishes Serine/threonine-protein
FT                                kinase activity.
FT   MUTAGEN     644    644       K->R: Substantial reduction of
FT                                autophosphorylation.
FT   CONFLICT    191    191       G -> D (in Ref. 2; AAB33345/AAC50209).
FT   CONFLICT    562    562       S -> P (in Ref. 3; BAG36611).
FT   CONFLICT    736    736       I -> T (in Ref. 6; no nucleotide entry).
FT   CONFLICT    750    750       T -> A (in Ref. 6; no nucleotide entry).
FT   CONFLICT    800    800       G -> A (in Ref. 6; no nucleotide entry).
FT   CONFLICT    812    812       E -> G (in Ref. 3; BAG36611).
FT   CONFLICT    887    887       L -> P (in Ref. 3; BAG53845).
FT   HELIX        15     18
FT   HELIX        29     66
FT   HELIX        71     95
FT   HELIX       124    153
FT   HELIX       160    192
FT   STRAND      194    196
SQ   SEQUENCE   942 AA;  103932 MW;  61360295EC70BB8E CRC64;
     MASDAVQSEP RSWSLLEQLG LAGADLAAPG VQQQLELERE RLRREIRKEL KLKEGAENLR
     RATTDLGRSL GPVELLLRGS SRRLDLLHQQ LQELHAHVVL PDPAATHDGP QSPGAGGPTC
     SATNLSRVAG LEKQLAIELK VKQGAENMIQ TYSNGSTKDR KLLLTAQQML QDSKTKIDII
     RMQLRRALQA GQLENQAAPD DTQGSPDLGA VELRIEELRH HFRVEHAVAE GAKNVLRLLS
     AAKAPDRKAV SEAQEKLTES NQKLGLLREA LERRLGELPA DHPKGRLLRE ELAAASSAAF
     STRLAGPFPA THYSTLCKPA PLTGTLEVRV VGCRDLPETI PWNPTPSMGG PGTPDSRPPF
     LSRPARGLYS RSGSLSGRSS LKAEAENTSE VSTVLKLDNT VVGQTSWKPC GPNAWDQSFT
     LELERARELE LAVFWRDQRG LCALKFLKLE DFLDNERHEV QLDMEPQGCL VAEVTFRNPV
     IERIPRLRRQ KKIFSKQQGK AFQRARQMNI DVATWVRLLR RLIPNATGTG TFSPGASPGS
     EARTTGDISV EKLNLGTDSD SSPQKSSRDP PSSPSSLSSP IQESTAPELP SETQETPGPA
     LCSPLRKSPL TLEDFKFLAV LGRGHFGKVL LSEFRPSGEL FAIKALKKGD IVARDEVESL
     MCEKRILAAV TSAGHPFLVN LFGCFQTPEH VCFVMEYSAG GDLMLHIHSD VFSEPRAIFY
     SACVVLGLQF LHEHKIVYRD LKLDNLLLDT EGYVKIADFG LCKEGMGYGD RTSTFCGTPE
     FLAPEVLTDT SYTRAVDWWG LGVLLYEMLV GESPFPGDDE EEVFDSIVND EVRYPRFLSA
     EAIGIMRRLL RRNPERRLGS SERDAEDVKK QPFFRTLGWE ALLARRLPPP FVPTLSGRTD
     VSNFDEEFTG EAPTLSPPRD ARPLTAAEQA AFLDFDFVAG GC
//
